NovoCure (NVCR) Cash & Equivalents Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -9.44% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 19.87% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -36.69% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 36.60% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 40.99% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 34.11% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 21.52% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -0.70% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 28.25% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | -22.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.21% |
| Dec 31, 2025 | -6.74% |
| Sep 30, 2025 | 11.96% |
| Jun 30, 2025 | -25.85% |
| Mar 31, 2025 | -12.61% |
| Dec 31, 2024 | -7.78% |
| Sep 30, 2024 | -35.46% |
| Jun 30, 2024 | -22.14% |
| Mar 31, 2024 | 12.99% |
| Dec 31, 2023 | 0.87% |
| Sep 30, 2023 | -12.91% |
| Jun 30, 2023 | -7.26% |
| Mar 31, 2023 | 0.74% |
| Dec 31, 2022 | -13.36% |
| Sep 30, 2022 | 5.43% |
| Jun 30, 2022 | 26.79% |
| Mar 31, 2022 | 7.85% |
| Dec 31, 2021 | 14.08% |
| Sep 30, 2021 | 77.69% |
| Jun 30, 2021 | 45.03% |
| Mar 31, 2021 | 41.25% |
| Dec 31, 2020 | 44.00% |
| Sep 30, 2020 | 41.87% |
| Jun 30, 2020 | 34.88% |
| Mar 31, 2020 | 29.08% |
| Dec 31, 2019 | 21.13% |
| Sep 30, 2019 | 21.56% |
| Jun 30, 2019 | 30.58% |
| Mar 31, 2019 | 9.47% |
| Dec 31, 2018 | 5.60% |
| Sep 30, 2018 | 3.68% |
| Jun 30, 2018 | 2.43% |
| Mar 31, 2018 | 14.57% |
| Dec 31, 2017 | 10.91% |
| Sep 30, 2017 | 0.88% |